Covered Metal Stent for Benign Biliary Stricture Caused by Chronic Pancreatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01929538|
Recruitment Status : Recruiting
First Posted : August 28, 2013
Last Update Posted : January 16, 2017
|Condition or disease||Intervention/treatment||Phase|
|Biliary Stricture Chronic Pancreatitis||Procedure: ERCP Device: covered self-expanding biliary metal stent, 12mm in diameter Device: covered self-expanding biliary metal stent, 10mm in diameter||Not Applicable|
All consecutive patients admitted for ERCP and treated for benign biliary stricture caused by chronic pancreatitis with or without acute pancreatitis are prospectively enrolled in the study. The age and gender of the patients and the aetiology of the pancreatitis will be recorded.
At initial presentation, clinical and laboratory findings recorded include liver function tests, abdominal pain, jaundice and cholangitis. Pancreatic calcifications are documented in abdominal computed tomography. Patients with malignancies, cirrhosis, acute/chronic hepatitis or abnormal hepatic imaging studies are excluded. Patients with first attack of acute pancreatitis will be excluded.
The approval of the ethics committee of the hospital has been obtained. An informed consent will be obtained from all patients.
All patients are prepared and sedated for ERCP as per standard medical practice of the hospital. At the initial ERCP, an endoscopic sphincterotomy will be performed and the presence/absence of bile duct stones above the stricture and the treatment of stones are recorded. A pancreatic stent will be inserted if indicated. For the initial ERCP the patients will be randomized into two groups: those who receive 10 mm diameter cSEMS and those who receive 12 mm diameter cSEMS into the bile duct. For the randomization, sealed envelopes will be used. The length of the cSEMS is recorded.
Further ERCP for stent removal will be performed after six months for the patients with 12 mm diameter cSEMS and after twelve months for the patients with 10 mm diameter cSEMS. In case of stent migration during the follow-up, the stent will be replaced by a similar new cSEMS. If a pancreatic stent will be placed, the removal or replacement will be handled according to the hospital practice.
After each ERCP procedure, all patients will stay in hospital for monitoring the occurrence of primary complications such as acute pancreatitis and cholangitis, bile leak, bleeding or perforation. Plasma amylase activity is measured same day > 4h after ERCP. Post-ERCP pancreatitis is defined as the presence of abdominal pain attributable to acute pancreatitis and plasma amylase level at least three times above the upper limit of the reference interval. The treatment of primary complications is recorded.
Clinical response (adequate biliary drainage) and recurrent stricture formation are the primary endpoints of the study. Therefore, blood liver function tests (bilirubin, alkaline phosphatase) as well as the minimum diameter of the common bile duct in the area of the stricture, the maximum diameter of the common bile duct above the stricture and the length of the stricture are measured at ERCPs at the time of the initial ERCP and at removal of cSEMS. Blood liver function tests are measured in the morning before ERCPs; the exact widths and lengths in mm:s are obtained by comparison the widths and lengths with the diameter of the scope. In addition, blood liver function tests are measured and abdominal ultrasonography performed in the follow-up six months and two years after the stent removal.
Morbidity and mortality are additional endpoints of the study. Therefore, complications (deaths, stent occlusions, dislodgements or migrations, cholangitis, hemobilia, stone formation above the stent), management of complications, admission times, surgical interventions and any additional care needed are monitored and recorded during the follow-up time. Patients are asked to contact the physician at any time if symptoms such as fever, abdominal pain or jaundice occur.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Covered Self-expandable Metal Stent, 6 Versus 12 Months, for Benign Biliary Stricture Caused by Chronic Pancreatitis: a Prospective Randomized Study|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Active Comparator: Covered biliary metal stent, 12 mm
ERCP and placement of a covered self-expanding biliary metal stent, 12mm in diameter
endoscopic retrograde cholangiopancreatographyDevice: covered self-expanding biliary metal stent, 12mm in diameter
Active Comparator: covered Biliary metal stent, 10 mm
ERCP and placement of a covered self-expanding biliary metal stent, 10 mm in diameter
endoscopic retrograde cholangiopancreatographyDevice: covered self-expanding biliary metal stent, 10mm in diameter
- Stricture resolution of the common bile duct in the two study groups [ Time Frame: 2,5 years ]Stricture resolution during stenting and follow-up period, defined by normal liver function tests and abdominal ultrasonography
- Stent removability [ Time Frame: 1 year ]Ability to remove stents endoscopically after six months and one year without stent-removal related complications
- Occurrence of complications related to stents and procedure [ Time Frame: 2,5 years ]
- Biliary stricture Chronic pancreatitis [ Time Frame: 2,5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01929538
|Contact: Leena Kylänpää, MD, PhDemail@example.com|
|Helsinki University Central Hospital||Recruiting|
|Helsinki, Finland, 00029|
|Contact: Leena Kylänpää, MD, PhD +358-50-4272869 firstname.lastname@example.org|
|Sub-Investigator: Jorma Halttunen, MD, PhD|
|Sub-Investigator: Marianne Udd, MD, PhD|
|Sub-Investigator: Outi Lindström, MD, PhD|
|Principal Investigator:||Leena Kylänpää, MD, PhD||Helsinki University Central Hospital|